AEs / PIs / Boehringer Ingelheim Pharmaceuticals Inc. / abbreviations AE / RTV co / Pharmacia / C co / Abbott Laboratories / /
Country
Guinea / Canada / /
Currency
pence / /
Event
FDA Phase / Product Recall / Product Issues / /
Facility
LABORATORY EVALUATIONS OF PIVOTAL / Laboratory Adnormalities / /
IndustryTerm
drug product / study protocol / clinical trial protocols / pharmaceutical / decisions about relevant protocol / degradation products / control / food / transport systems / trial protocols / ingelheim pharmaceuticals / bulk fill solution / treatment of HIV / chemical name / /
MedicalCondition
HIV / advanced HIV disease taking / advanced HIV disease / HIV RNA 1 / 000 / HIV epidemic / diarrhea / HIV infection / necrosis / T-cell infection / tumors / Chronic / thyroid tumors / chronic therapy demonstrating / vomiting / hepatic failure / clinical hepatitis / AIDS / infection / increased ALT / chronic Hepatitis B / cholestasis / /
MedicalTreatment
drug delivery system / Highly active antiretroviral therapy / HAART / dialysis / /
Organization
Excretion Administration / U.S. Securities and Exchange Commission / BID administration / FDA / RTV administration / TPV administration / /
Position
investigator / consultant / General / representative / investigator for the RESIST trial / /
study protocol / Genotyping / trial protocols / chain reaction PEY Person exposure years PI Protease inhibitor PK Pharmacokinetics PPS Per protocol / clinical trial protocols / Pharmacokinetics / drug delivery system / Genotype / drug development / dialysis / /
Boehringer Ingelheim Pharmaceuticals, Inc. Tipranavir Capsules NDA[removed]Antiviral Drugs Advisory Committee Briefing Document, April 19, 2005 Boehringer Ingelheim Pharmaceuticals, Inc.